Literature DB >> 10913398

Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review.

G Nigro1, V Bastianon, V Colloridi, F Ventriglia, P Gallo, G D'Amati, W C Koch, S P Adler.   

Abstract

Human parvovirus B19 infection is occasionally associated with acute lymphocytic myocarditis (ALM). Three infants with B19 virus-associated ALM were followed up clinically, histologically, and immunovirologically. Each infant had B19 virus DNA in the blood or B19 virus-specific IgM antibodies. Two infants with postnatal infection recovered after immunosuppressive therapy. The third infant with possible prenatal infection developed chronic persistent myocarditis associated with persistent B19 virus DNA in the blood. All 3 infants had increased levels of interferon-gamma, tumor necrosis factor-alpha, and interleukins -6 and -8. Four newborns with congenital B19 virus infection and 4 infants and children who had postnatally acquired B19 virus infection without myocarditis all had normal levels of these cytokines. These observations suggest that B19 virus infection in infancy causes ALM in some infants and children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913398     DOI: 10.1086/313929

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

1.  Use of intravenous immunoglobulin in critically ill patients.

Authors:  Summer Donovan; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

2.  Lethal influenza B myocarditis in a child and review of the literature for pediatric age groups.

Authors:  H Frank; C Wittekind; U G Liebert; M Siekmeyer; W Siekmeyer; V Schuster; W Kiess
Journal:  Infection       Date:  2010-04-01       Impact factor: 3.553

3.  T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Authors:  R Franssila; J Auramo; S Modrow; M Möbs; C Oker-Blom; P Käpylä; M Söderlund-Venermo; K Hedman
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 4.  Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy.

Authors:  W Poller; U Kühl; C Tschoepe; M Pauschinger; H Fechner; H-P Schultheiss
Journal:  J Mol Med (Berl)       Date:  2005-06-02       Impact factor: 4.599

Review 5.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 6.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

7.  Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q.

Authors:  Kristina von Kietzell; Tanja Pozzuto; Regine Heilbronn; Tobias Grössl; Henry Fechner; Stefan Weger
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

Review 8.  Viral myocarditis: from experimental models to molecular diagnosis in patients.

Authors:  Sabine Pankuweit; Karin Klingel
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

9.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

10.  Increased expression and secretion of interleukin-6 in human parvovirus B19 non-structural protein (NS1) transfected COS-7 epithelial cells.

Authors:  T-C Hsu; B-S Tzang; C-N Huang; Y-J Lee; G-Y Liu; M-C Chen; G J Tsay
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.